Although GRN mutation carriers are associated with lower PGRN concentrations, we found that across multiple neurodegenerative diseases PGRN levels were generally higher than a control population e.g. in AD and non-GRN-FTD, as reported in a previous multicentre Italian study [14]. This evidence concerns the gene GRN and frontotemporal dementia.